• 84% Sensitivity. 94% Specificity. 98% NPV.

  • Science behind iBreastExam

    Ingredients: Coffee + Base of Support + Dash of Luck = Innovation

    Invented at Drexel University, Philadelphia.

    iBreastExam's sensors accurately assess & identify tissue elasticity differences between hard & stiff breast tumors versus normal breast tissue. The patented tactile sensor technology using Piezoelectric Sensor Array was invented by the scientists and doctors at Drexel University. It is a novel, quantitative and low-cost elastic modulus (E) sensor that can measure tissue compression and stiffness by top down touching of the skin surface. iBE’s ability to apply a gentle force and measure the subtle displacements electrically, all within the sensor, makes for an ideal ‘electronic palpation’ sensor for in-vivo breast imaging.

     

    Translational research and commercialization of iBreastExam innovation is backed by R&D funding from:

    • Drexel University, Philadelphia (Coulter Program)
    • University City Science Center, Philadelphia (QED & DHA)
    • Pennsylvania Department of Health, USA (CURE Grant)
    • Pfizer Foundation & Unitus Ventures, USA (StartHealth)
  • Published Studies

    World Journal of Surgical Oncology (WJSO), Indian Journal of Gynecologic Oncology (IJGO)

    & Journal of American College of Surgeons (JACS)

    World Journal of Surgical Oncology (2016)

    Another clinical study titled "A cost-effective handheld breast scanner for use in low-resource environments: a validation study" published in the World Journal of Surgical Oncology on Oct 28, 2016. iBE correctly identified 66 lesions demonstrating sensitivity of 86% and specificity of 89%.

    Indian Journal of Gynecologic Oncology (2016)

    A major clinical study evaluating iBE™ technology was published in the Indian Journal of Gynecologic Oncology in June 2016. The study showed that iBreastExam device can significantly enhance clinical breast examination Sensitivity (by 19%) while maintaining high Specificity (94%) and Negative Predictive Value (NPV) of 98%. The study concluded that iBreastExam can be a promising tool for early detection of clinically relevant lesions at early stages and also useful in younger women with dense breasts.

    Journal of the American College of Surgeons (2013)

    The first clinical study evaluating iBE technology was published in the Journal of the American College of Surgeons (Volume 216, Issue 6, Pages 1168-1173, June 2013). This study demonstrated that iBE technology could confidently detect invasive lesions/tumors that the physician could not feel with his hands (meaning non-palpable lesions). iBE also performed very well in the younger age group (below 40) in detecting small masses.

  • Large Scale Implementations

    in collaboration with Public Health Agencies

    Enrolled 74,500+ women at 16 Medical Colleges in Maharashtra

    In collaboration with Malabar Cancer Center (coming soon)

    Project with Aam Aadmi Mohalla Clinics, Delhi Gov.

  • Researchers & Clinicians

    IP, Grants, Design, R&D

    Kiran Mazumdar-Shaw, Ranjan Pai, Unitus Ventures

  • See iBreastExam in action!

All Posts
×